Imatinib kezelési eredmények krónikus myeloid leukaemia késoi krónikus fázisában, interferon-α kezelés után

Translated title of the contribution: Imatinib treatment of late chronic phase CML patients after interferon-α in Hungary

Lenke Molnár, Ágnes Nagy, Marianna Dávid, Árpád Szomor, Gábor Méhes, Gábor Kovács, Hajna Losonczy

Research output: Contribution to journalArticle


Background: Chronic myelogenous leukemia is characterised by the presence of Philadelphia translocation and consecutive expression of bcr-abl oncogene with enhanced tyrosine kinase activity, which is known to be the essential pathogenetic event in the disease. Imatinib (Glivec, formerly STI571) is a highly selective inhibitor of the bcr-abl tyrosine kinase which has shown a promising therapeutic activity in chronic myeloid leukemia as the first molecularly targeted antineoplastic treatment. Methods: Between January 2001 and October 2001, 54 patients with chronic phase CML, resistant or intolerant to interferon-α were enrolled into the Novartis Expanded Access Study (Protocol 0113). Patients characteristics were as follows: male/female: 32/22, median age: 49 years (range: 22-75), median duration of disease: 44 months (range: 3-152). All patients received 400 mg imatinib orally. Results: Complete hematologic response was obtained in 53 patients (96%) within 4 weeks. Major cytogenetic response (< 35% Ph+ metaphasis) was achieved after 6 months in 62.9%, and after 12 months in 64.8% of patients. Three patients progressed during the treatment (loss of complete hematologic response or cytogenetic response 1, blastic phase 2). The treatment was well tolerated, with mild side effects. Main non-hematologic side effects were weight gain and fluid retention. Conclusions: The results confirm that imatinib is highly active in inducing complete hematologic response and major cytogenetic response in most patients who failed interferon-α. Treatment was well tolerated with rare and mild adverse events and impressive improvement of quality of life.

Translated title of the contributionImatinib treatment of late chronic phase CML patients after interferon-α in Hungary
Original languageHungarian
Pages (from-to)901-907
Number of pages7
JournalOrvosi hetilap
Issue number17
Publication statusPublished - Apr 1 2004

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Imatinib treatment of late chronic phase CML patients after interferon-α in Hungary'. Together they form a unique fingerprint.

  • Cite this